Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.47 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487468 | 0.85 | IDO1 (0.48) | CYP3A4 | |
| SCHEMBL1697126 | 0.85 | MAPT (0.64) | HTR7KDM4ECYP3A4MAPTMRGPRX4 | |
| Hydrochloric Acid SCHEMBL3273205 | 0.83 | MAPT (0.68) | HTR7KDM4ECYP3A4MAPTMRGPRX4 | |
| SCHEMBL18884349 | 0.82 | CYP3A4 (0.58) | KDM4ECYP3A4MAPT | |
| SCHEMBL18745617 | 0.82 | NOS1 (0.46) | HTR7NOS1NOS3 | |
| SCHEMBL8338395 | 0.79 | MRGPRX4 (0.48) | HTR7KDM4ECYP3A4MAPTMRGPRX4 | |
| SCHEMBL13930293 | 0.79 | LOXL2 (0.50) | HTR7KDM4ECYP3A4MAPTNOS1 | |
| SCHEMBL20795015 | 0.78 | LTA4H (0.45) | — | |
| SCHEMBL8441355 | 0.77 | KDM4E (0.54) | HTR7KDM4ECYP3A4MAPTMRGPRX4 | |
| SCHEMBL12305 | 0.77 | TP53 (0.44) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3756464-A1 | SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3151669-B1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20200283398-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-2826777-B1 | EPOXY COMPOUND HAVING ALKOXY SILYL GROUP, COMPOSITION COMPRISING SAME, CURED PRODUCT, USE THEREOF AND METHOD FOR PREPARING EPOXY COMPOUND HAVING ALKOXY SILYL GROUP | KOREA INST IND TECH (KR) | 2020-08-05 | — | — | EP | disclosed |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283398-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | HTR7 4372/4885KDM4E 4025/4885CYP3A4 1294/4885 |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | HTR7 4372/4885KDM4E 4025/4885CYP3A4 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.